Last Updated:
Searching
Create account to add to watchlist!

Ignyte Acquisition Corp. - IGNY

  • Commons

    $9.81

    +0.31%

    IGNY Vol: 0.0

  • Warrants

    $0.80

    -8.94%

    IGNYW Vol: 0.0

  • Units

    $10.03

    -2.81%

    IGNYU Vol: 1.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 71.5M
Average Volume: 9.6K
52W Range: $9.58 - $9.98
Weekly %: +0.20%
Monthly %: +0.00%
Inst Owners: 15

Info

Target: Searching
Days Since IPO: 304
Unit composition:
Each unit consists of one share of common stock and one-half of one warrant
Trust Size: 5000000.0M

Management

Our current directors and executive officers are as follows: Name Age Title David I. Rosenberg 47 Chairman of the Board and Co-Chief Executive Officer David J. Strupp, Jr. 52 Co-Chief Executive Officer and Director Steven Kaplan 57 Chief Financial Officer and Director Cheryl Cohen 54 Director Charles Wilson, Ph.D. 56 Director John Andrew Boockvar, M.D. 49 Director Richard J. Rosenstock 69 Director David I. Rosenberg has been our Chairman of the Board and co-Chief Executive Officer since our formation. Mr. Rosenberg brings over 20 years of investment banking experience focused on growth companies. Since December 2011, Mr. Rosenberg has been Co-President and Co-Chief Executive Officer of Ladenburg Thalmann & Co. Inc., a leading underwriter of blank check companies or SPACs. Mr. Rosenberg is also a member of Board of Directors of Ladenburg Thalmann & Co. Inc. From 2006 to 2011, Mr. Rosenberg was a Managing Director and Co-Chief Operating Officer of Ladenburg Thalmann & Co. Inc. Since joining Ladenburg Thalmann in 2006, Mr. Rosenberg has managed more than 1,000 public offerings including but not limited to initial public offerings and follow on offerings raising in excess of $75 billion for small and mid-cap companies, as well as advising on numerous merger and acquisition transactions. Mr. Rosenberg also serves as member of the Board of Directors of Dianomi Therapeutics. Prior to joining Ladenburg Thalmann, from 2004 to 2006, Mr. Rosenberg was co-founder and Chief Executive Officer of BroadWall Capital, LLC, an investment banking firm. Mr. Rosenberg received a B.A. from the University of Wisconsin-Madison. We believe Mr. Rosenberg is well qualified to serve on our board of directors because of his significant investment banking, equity capital markets and executive management experience. Mr. Rosenberg is the nephew of Richard Rosenstock, one of our directors. 68 David J. Strupp, Jr. has been our Co-Chief Executive Officer and a member of our board of directors since our formation. Mr. Strupp has worked as a dedicated healthcare investment banker for over 27 years at various investment banks. Mr. Strupp has served as a Managing Director and Head of Healthcare Investment Banking at Ladenburg Thalmann & Co. Inc. since May 2012. In his role leading the firm’s healthcare investment banking practice at Ladenburg Thalmann, Mr. Strupp has overseen the execution of numerous transactions across a range of products, including M&A advisory, equity and equity-linked offerings, private placements and fixed income transactions. During his tenure at Ladenburg Thalmann, Mr. Strupp has helped the firm establish a market-leading practice advising biotechnology companies in reverse merger transactions. Prior to joining Ladenburg Thalmann, Mr. Strupp worked as a senior member of the healthcare groups at boutique investment banks, including ThinkEquity Partners from 2002 to 2007, Canaccord Adams (now Canaccord Genuity) from 2007 to 2008, the Maxim Group from 2008 to 2009, and Rodman & Renshaw from 2009 to 2012. He began his career on Wall Street working in the healthcare groups at UBS Securities from 1993 to 1998, NationsBanc Montgomery Securities from 1998 to 1999, and Citigroup from 1999 to 2002. Mr. Strupp received a B.A. in Economics from Bates College and an M.Sc. in Economics from the London School of Economics. We believe Mr. Strupp is well-qualified to serve on our board of directors due to his experience as a dedicated healthcare investment banker and expertise in reverse merger transactions. Steven N. Kaplan has been our Chief Financial Officer and director since October 2020. Mr. Kaplan joined Ladenburg Thalmann & Co. Inc. as a Managing Director in September 2004 and was promoted to Head of Capital Markets in December 2011. Mr. Kaplan co-heads the investment banking group at Ladenburg Thalmann which focuses on blank check companies or SPACs. Prior to joining Ladenburg Thalmann, Mr. Kaplan had substantial experience advising companies in the healthcare services industry. From 1999 to 2004, Mr. Kaplan was a Co-Founder and a Partner of River Capital Partners, a healthcare services focused M&A advisory firm. From 1996 to 1999, he was a Vice President in the Healthcare Investment Banking Group of Prudential Securities. From 1993 to 1996 he was an associate at Jefferies & Company, primarily focused on Healthcare M&A. He previously worked at auditing firms Pricewaterhouse and Deloitte & Touche. Over the course of his career, Mr. Kaplan has managed over 500 public offerings including but not limited to IPOs and follow-on offerings as well as advising on numerous merger and acquisition transactions. Mr. Kaplan received a BSBA from Babson College and an MBA from the University of North Carolina Chapel Hill. Cheryl L. Cohen has served as a member of our board of directors since November 2020. Ms. Cohen has more than 25 years of leadership experience within the pharmaceutical and biotechnology industries. Ms. Cohen currently serves as President of CLC Consulting, a pharmaceutical and biotechnology consulting firm which she founded in July 2008. From September 2011 to July 2014, Ms. Cohen served as Chief Commercial Officer of Medivation, Inc., a publicly traded bio-pharmaceutical company. Prior to joining Medivation, Ms. Cohen spent over 10 years at Johnson & Johnson. From November 2007 to September 2008, she served as the Vice President, strategic commercial group, of Health Care Systems, Inc., a Johnson & Johnson company, and from October 1998 to November 2007, she worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), a Johnson & Johnson company, in a variety of senior executive roles including Vice President, rheumatology franchise. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of management and sales positions. In addition, Ms. Cohen currently serves on the board of directors of Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO), a public pharmaceutical company, since 2018 and NantKwest (NASDAQ: NK), a public pharmaceutical company, since June 2019 and MEI Pharma, Inc. (NASDAQ: MEIP), a public pharmaceutical company since June 2020. She previously served on the boards of directors of Novus Therapeutics, Inc. (reverse merger of Tokai Pharmaceuticals, Inc) from April 2015 to June 2020, Vital Therapies, Inc., a therapeutics company, from 2015 until 2019, Cytrx Corporation, a publicly traded biopharmaceutical company from June 2015 through October 2016, and Protein Sciences Corporation, a privately held bio-pharmaceutical company from October 2014 to August 2017. Ms. Cohen received a B.A. from Saint Joseph College. We believe Ms. Cohen is well-qualified to serve on our board of directors due to her public and private company experience and relationships and contacts. Charles (“Chuck”) Wilson, Ph.D. has served as a member of our board of directors since November 2020. From 2014 to 2020, Dr. Wilson served as President and Chief Executive Officer of Unum Therapeutics Inc. (now named Cogent Biosciences, Inc.), a company developing novel therapies for the treatment of cancer. From 2008 to 2014, Dr. Wilson served as Vice President, Global Head of Strategic Alliances for the Novartis Institutes for BioMedical Research (NIBR), the research and early development division of Novartis. In this role he was responsible for leading partnering efforts across all disease areas up through clinical proof-of-concept. His efforts included academic and biotech collaborations, equity investing in early stage companies, in-licensing of compounds, and spin-out of assets/ 69 technologies to start ups. In 2001, Dr. Wilson co-founded Archemix, a Cambridge, MA biotech company focused on the development of aptamers as therapeutics, and served as its Chief Technology Officer where he was responsible for both developing the company’s technology platform and managing its drug discovery efforts. As part of the senior management team, Dr. Wilson helped the company raise over $100 million in equity financing and advance multiple programs into clinical development. Before moving into industry, Dr. Wilson was a professor in the Markey Center for the Molecular Biology of RNA at the University of California, Santa Cruz from 1994 to 2001. Trained in structural biology and molecular biology, Dr. Wilson received a PhD with David Agard (UCSF, HHMI) and received his postdoctoral training with Nobelist Jack Szostak (Havard University / Massachusetts General Hospital). He received a B.A. and M.A. from Boston University. He currently serves as Board Chair for the Massachusetts Biotechnology Council and as a member of the Board for GigaGen, Inc. We believe Dr. Wilson is well-qualified to serve on our board of directors due to his experience and relationships and contacts. John Andrew Boockvar, M.D. has served as a member of our board of directors since November 2020. Since 2015, Dr. Boockvar has served as the Vice Chair of the Department of Neurosurgery at Lenox Hill Hospital and Director of the Brain Tumor Center, and the Pituitary/Neuroendocrine Center of the Department of Neurosurgery and the New York Head and Neck Institute at Lenox Hill and Manhattan Eye, Ear and Throat Hospitals. Dr. Boockvar has also been a Professor of Neurological Surgery and Otolaryngology/Head and Neck Surgery at the Zucker School of Medicine since 2014. He has also been an investigator at the Feinstein Institutes for Medical Research since 2014 where he directs the Laboratory for Brain Tumor Biology and Therapy. Dr. Boockvar is internationally known for his surgical expertise and for providing patients with safe, effective, and minimally invasive treatment for brain tumors, skull base disorders, and disorders of the spine. Dr. Boockvar’s surgical expertise is in benign and malignant brain tumors, skull base and endoscopic pituitary surgery, spinal and peripheral nerve tumors, minimally invasive spinal surgery, and complex spinal disorders. Dr. Boockvar has been recognized for his novel research in brain tumors and stem cell biology. Dr. Boockvar has been repeatedly named to the lists of New York Magazine’s Top Docs, Best Doctors in New York-Castle Connolly, New York Super Doctors (2020), America’s Top Surgeons, America’s Best Doctors, and America’s Best Doctors for Cancer. His research has been widely published and he has received numerous national awards including the Eric Lichtenstein Humanitarian Award from Voices Against Brain Cancer for his compassionate work in treating patients with brain cancer. In 2016, Dr. Boockvar was elected to the Academy of Neurological Surgeons. In 2017, he was elected to the Senior Society of the American Board of Neurological Surgery. Dr. Boockvar is the star in Netflix’s nine-part docuseries, Lenox Hill, and has been featured on special episodes of the Dr. Oz Show on brain tumors. Medical Mysteries, Good Morning America and the Today Show with Megyn Kelly. He also founded and hosts his own interactive webinar, “ByTheBoock” featuring special guests ranging from CEOs of major companies, authors, biotech experts and more. Dr. Boockvar is also an honorary surgeon of the NYPD and the New York State Troopers. He received a B.A. from the University of Pennsylvania. We believe Mr. Boockvar is well-qualified to serve on our board of directors due to his experience and relationships and contacts. Richard J. Rosenstock has served as a member of our board of directors since November 2020. Since 2006, Mr. Rosenstock has served as managing member of Encore Atlantic Fund, LLC, a hedge fund he founded that invests primarily in SPACs. From May 2001 until December 2002, he served as Vice Chairman and Chief Operating Officer of Ladenburg Thalmann Financial Services Inc., a formerly publicly traded financial services company, and served as its President from August 1999 until May 2001. He also served on its board of directors from 1999 to March 2015. Mr. Rosenstock received a B.S. from Northeastern University. We believe Mr. Rosenstock is well-qualified to serve on our board of directors due to his investment banking experience and relationships and contacts. Mr. Rosenstock is the uncle of Mr. Rosenberg. Our board of directors is divided into three classes with only one class of directors being elected in each year and each class serving a three-year term. The term of office of the first class of directors, consisting of Cheryl Cohen and Charles Wilson, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Richard J. Rosenstock and John Andrew Boockvar, will expire at the second annual meeting. The term of office of the third class of directors, consisting of David Rosenberg, David J. Strupp, Jr. and Steven Kaplan, will expire at the third annual meeting. 70 Executive Compensation No executive officer has received any cash compensation for services rendered to us. Commencing on the date of this prospectus through the acquisition of a target business or our liquidation of the trust account, we will pay our sponsor $10,000 per month for providing us with office space and certain office and secretarial services. However, this arrangement is solely for our benefit and is not intended to provide our officers or directors compensation in lieu of a salary. Other than the $10,000 per month administrative fee, the payment of consulting, success or finder fees to our sponsor, officers, directors, initial stockholders or their affiliates in connection with the consummation of our initial business combination and the repayment of loans made by our executive officers to us as of the date of this prospectus, no compensation or fees of any kind will be paid to our sponsor, initial stockholders, members of our management team or their respective affiliates, for services rendered prior to or in connection with the consummation of our initial business combination (regardless of the type of transaction that it is). However, they will receive reimbursement for any out-of-pocket expenses incurred by them in connection with activities on our behalf, such as identifying potential target businesses, performing business due diligence on suitable target businesses and business combinations as well as traveling to and from the offices, plants or similar locations of prospective target businesses to examine their operations. There is no limit on the amount of consulting, success or finder fees payable by us upon consummation of an initial business combination. Additionally, there is no limit on the amount of out-of-pocket expenses reimbursable by us; provided, however, that to the extent such expenses exceed the available proceeds not deposited in the trust account, such expenses would not be reimbursed by us unless we consummate an initial business combination. After our initial business combination, members of our management team who remain with us may be paid consulting, management or other fees from the combined company with any and all amounts being fully disclosed to stockholders, to the extent then known, in the proxy solicitation materials furnished to our stockholders. However, the amount of such compensation may not be known at the time of the stockholder meeting held to consider an initial business combination, as it will be up to the directors of the post-combination business to determine executive and director compensation. In this event, such compensation will be publicly disclosed at the time of its determination in a Current Report on Form 8-K or a periodic report, as required by the SEC. Director Independence Currently Ms. Cohen, Dr. Wilson, Dr. Boockvar and Mr. Rosenstock would each be considered an “independent director” under the Nasdaq listing rules, which is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company’s board of directors would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Any affiliated transactions will be on terms no less favorable to us than could be obtained from independent parties. Our board of directors will review and approve all affiliated transactions with any interested director abstaining from such review and approval. Audit Committee Effective upon the date of this prospectus, we will establish an audit committee of the board of directors, which will consist of Mr. Rosenstock, Ms. Cohen and Dr. Wilson, each of whom is an independent director under Nasdaq’s listing standards. The audit committee’s duties, which are specified in our Audit Committee Charter, include, but are not limited to: ● reviewing and discussing with management and the independent auditor the annual audited financial statements, and recommending to the board whether the audited financial statements should be included in our Form 10-K; ● discussing with management and the independent auditor significant financial reporting issues and judgments made in connection with the preparation of our financial statements; 71 ● discussing with management major risk assessment and risk management policies; ● monitoring the independence of the independent auditor; ● verifying the rotation of the lead (or coordinating) audit partner having primary responsibility for the audit and the audit partner responsible for reviewing the audit as required by law; ● reviewing and approving all related-party transactions; ● inquiring and discussing with management our compliance with applicable laws and regulations; ● pre-approving all audit services and permitted non-audit services to be performed by our independent auditor, including the fees and terms of the services to be performed; ● appointing or replacing the independent auditor; ● determining the compensation and oversight of the work of the independent auditor (including resolution of disagreements between management and the independent auditor regarding financial reporting) for the purpose of preparing or issuing an audit report or related work; ● establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or reports which raise material issues regarding our financial statements or accounting policies; and ● approving reimbursement of expenses incurred by our management team in identifying potential target businesses. Financial Experts on Audit Committee The audit committee will at all times be composed exclusively of “independent directors” who are “financially literate” as defined under Nasdaq’s listing standards. Nasdaq’s standards define “financially literate” as being able to read and understand fundamental financial statements, including a company’s balance sheet, income statement and cash flow statement. In addition, we must certify to Nasdaq that the committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication. The board of directors has determined that Mr. Rosenstock qualifies as an “audit committee financial expert,” as defined under rules and regulations of the SEC. Nominating Committee Effective upon the date of this prospectus, we will establish a nominating committee of the board of directors, which will consist of Ms. Cohen, Dr. Wilson, Dr. Boockvar and Mr. Rosenstock, each of whom is an independent director under Nasdaq’s listing standards. The nominating committee is responsible for overseeing the selection of persons to be nominated to serve on our boar

Holder Stats

1 0
% of Shares Held by All Insider 17.15%
% of Shares Held by Institutions 20.82%
% of Float Held by Institutions 25.13%
Number of Institutions Holding Shares 15

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Millennium Management LLC 49,347 $480,000 0.0% +33.9% 2.544%
2021-11-16 Citadel Advisors LLC 111,259 $1,090,000 0.0% -3.2% 5.735%
2021-11-15 Deerfield Management Company L.P. Series C 725,000 $7,100,000 0.1% 0 37.371%
2021-11-15 Rivernorth Capital Management LLC 20,000 $200,000 0.0% 0 1.031%
2021-11-15 Berkley W R Corp 114,744 $1,960,000 0.1% 0 5.915%
2021-11-15 Dark Forest Capital Management LP 35,216 $350,000 0.1% 0 1.815%
2021-11-12 Wolverine Asset Management LLC 41,792 $410,000 0.0% +803.8% 2.154%
2021-11-12 K2 Principal Fund L.P. 412,651 $4,040,000 0.3% +19.8% 21.271%
2021-11-12 Cohanzick Management LLC 73,737 $720,000 0.2% +46.3% 3.801%
2021-11-10 Goldman Sachs Group Inc. 24,152 $240,000 0.0% 0 1.245%
2021-11-09 Picton Mahoney Asset Management 40,000 $390,000 0.0% 0 2.062%
2021-11-09 Basso Capital Management L.P. 114,310 $1,120,000 0.1% +12.0% 5.892%
2021-08-17 Millennium Management LLC 36,847 $360,000 0.0% 0 1.899%
2021-08-17 ATW Spac Management LLC 100,000 $970,000 0.2% 0 5.155%
2021-08-17 Boothbay Fund Management LLC 101,200 $980,000 0.0% 0 5.216%
2021-08-16 Cohanzick Management LLC 50,400 $490,000 0.2% 0 2.598%
2021-08-13 Basso Capital Management L.P. 102,100 $990,000 0.1% +96.0% 5.263%
2021-08-03 Landscape Capital Management L.L.C. 33,112 $320,000 0.0% 0 1.707%
2021-05-18 Karpus Management Inc. 162,100 $1,560,000 0.0% 0 8.356%
2021-05-18 Citadel Advisors LLC 114,806 $1,110,000 0.0% 0 5.918%
2021-05-18 Radcliffe Capital Management L.P. 100,000 $970,000 0.0% 0 5.155%
2021-05-18 Jane Street Group LLC 55,140 $530,000 0.0% 0 2.842%
2021-05-17 Saba Capital Management L.P. 149,700 $1,450,000 0.0% 0 7.716%
2021-05-17 Polar Asset Management Partners Inc. 75,000 $720,000 0.0% 0 3.866%
2021-05-14 K2 Principal Fund L.P. 143,436 $1,380,000 0.1% 0 7.394%
2021-05-14 Periscope Capital Inc. 150,000 $1,450,000 0.1% 0 7.732%
2021-05-14 Bulldog Investors LLP 25,000 $240,000 0.1% 0 1.289%

SEC Filings

Form Type Form Description Filing Date Document Link
8-K CURRENT REPORT 2021-11-16 https://www.sec.gov/Archives/edgar/data/1834645/000120677421002749/ignyte3984371-8k.htm
10-Q QUARTERLY REPORT 2021-11-15 https://www.sec.gov/Archives/edgar/data/1834645/000120677421002746/ignyte3973091-10q.htm
10-Q QUARTERLY REPORT 2021-08-16 https://www.sec.gov/Archives/edgar/data/1834645/000120677421002187/igny3944891-10q.htm
10-Q QUARTERLY REPORT 2021-07-26 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001837/ignyte3936331-10q.htm
8-K CURRENT REPORT 2021-07-15 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001712/ignyte3932331-8k.htm
SC 13G 2021-07-15 https://www.sec.gov/Archives/edgar/data/1834645/000146179021000028/13G_IGNY_20210714.htm
8-K CURRENT REPORT 2021-06-01 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001533/ignyte3915281-8k.htm
NT 10-Q NOTICE UNDER RULE 12B25 OF INABILITY TO TIMELY FILE ALL OR PART OF A FORM 10-Q 2021-05-17 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001473/ignyte3910631-nt10q.htm
10-K/A AMENDMENT TO ANNUAL REPORT 2021-04-19 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001133/ignyte3897661-10ka.htm
10-K ANNUAL REPORT 2021-04-15 https://www.sec.gov/Archives/edgar/data/1834645/000120677421001116/ignyte3897661-10k.htm
NT 10-K NOTICE UNDER RULE 12B25 OF INABILITY TO TIMELY FILE 2021-03-31 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000936/igny3890511-nt10k.htm
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 2021-03-12 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000700/xslF345X03/strupp3882141-form4.xml
4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 2021-03-12 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000689/xslF345X03/ownership.xml
8-K CURRENT REPORT 2021-03-10 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000652/ignyte3882131-8k.htm
SC 13G SC 13G 2021-02-25 https://www.sec.gov/Archives/edgar/data/1834645/000110465921027604/tm217879d1_sc13g.htm
8-K CURRENT REPORT 2021-02-08 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000315/ignyte3865751-8k.htm
3 2021-02-03 https://www.sec.gov/Archives/edgar/data/1834645/000119380521000130/xslF345X02/e620252_3-ignyte.xml
SC 13G 2021-02-03 https://www.sec.gov/Archives/edgar/data/1834645/000119380521000128/e620253_sc13g-ignyte.htm
SC 13G SC 13G 2021-02-02 https://www.sec.gov/Archives/edgar/data/1834645/000110465921010481/tm214971d1_sc13g.htm
3 PRIMARY DOCUMENT 2021-02-01 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000077/xslF345X02/edgar.xml
8-K CURRENT REPORT 2021-02-01 https://www.sec.gov/Archives/edgar/data/1834645/000135994821000009/ignyte3863651-8k.htm
424B4 PROSPECTUS FILED PURSUANT TO RULE 424(B)(4) 2021-01-28 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000239/ignyte3840331-424b4.htm
3 PRIMARY DOCUMENT 2021-01-28 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000075/xslF345X02/edgar.xml
EFFECT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/999999999521000307/xslEFFECTX01/primary_doc.xml
3 PRIMARY DOCUMENT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000073/xslF345X02/edgar.xml
3 PRIMARY DOCUMENT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000071/xslF345X02/edgar.xml
3 PRIMARY DOCUMENT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000068/xslF345X02/edgar.xml
3 PRIMARY DOCUMENT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000109489121000066/xslF345X02/edgar.xml
CERT 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000135445721000115/8A_Cert_IGNY.pdf
8-A12B REGISTRATION OF SECURITIES PURSUANT TO SECTION 12(B) 2021-01-27 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000221/ignyte3840335-8a12b.htm
S-1 GENERAL FORM OF REGISTRATION STATEMENT FOR ALL COMPANIES 2021-01-11 https://www.sec.gov/Archives/edgar/data/1834645/000120677421000066/ignyte3840331-s1.htm
DRS 2020-12-09 https://www.sec.gov/Archives/edgar/data/1834645/000120677420003154/filename1.htm